Status:
NOT_YET_RECRUITING
What is the Prognostic Value of HALP Score, Monocytopenia, Hypofibrinogenemia, and AST/ALT Ratio in Patients With Myelodysplastic Syndromes
Lead Sponsor:
Assiut University
Conditions:
Myelo Dysplastic Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
to investigate prognostic significance of many factors in MDS including HALP score ( haemoglobin level, albumin level, lymphocyte, platelets), monocytopenia, hyperfibrinogenemia and AST/ALT ratio in p...
Detailed Description
Frequently seen in advanced age, myelodysplastic syndromes (MDS) are a heterogeneous clonal stem cell disorders characterized by ineffective hematopoiesis and having a risk of progression to acute mye...
Eligibility Criteria
Inclusion
- • Adults (≥18 years old) diagnosed with MDS according to WHO criteria
- Availability of complete medical records including laboratory data for hemoglobin, albumin, lymphocyte count, platelet count, monocyte count, fibrinogen level, AST and ALT
- Patients who were followed for at least 12 months post-diagnosis or until death
Exclusion
- Patients with active infections, liver cirrhosis, chronic inflammatory diseases, or concurrent malignancies at time of diagnosis
- Incomplete laboratory or clinical data
- Patients lost to follow-up within less than 3 months of diagnosis
Key Trial Info
Start Date :
January 1 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2028
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07210034
Start Date
January 1 2026
End Date
March 1 2028
Last Update
October 7 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.